NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against Abbott Laboratories (“Abbott” or “the Company”) (NYSE : ABT) and certain of its officers on behalf of all individuals and entities that purchased or otherwise acquired Abbott securities between 19 February 2021 and 8 June 2022, both dates inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/abt.

This class action seeks damages against the defendants for alleged violations of federal securities laws.

The lawsuit alleges that during the class period, the defendants made numerous materially false and misleading statements and omissions regarding conditions at the Company’s Sturgis facility that the U.S. Food and Drug Administration (“FDA”) described as “extremely unsanitary”. have made. Specifically, the lawsuit alleges that the defendants repeatedly touted to investors the safety and salability of Abbott’s infant formula brands and their contribution to the company’s sales and earnings growth.

A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/abt or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss at Abbott, you have until October 31, 2022 to request that the court appoint you lead plaintiff. Your ability to participate in a recovery does not require you to serve as lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents investors in class action lawsuits alleging securities fraud and shareholder derivative lawsuits. The company has recovered hundreds of millions of dollars for investors nationwide. attorney advertising. Previous results do not guarantee similar results.

Contact:
Bronstein, …